RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Zelira Therapeutics Stock

Zelira Therapeutics P/E 2025

Zelira Therapeutics P/E

-0.12

Ticker

ZLD.AX

ISIN

AU000000ZLD1

WKN

A2AS5H

As of Jun 18, 2025, Zelira Therapeutics's P/E ratio was -0.12, a -36.84% change from the -0.19 P/E ratio recorded in the previous year.

The Zelira Therapeutics P/E history

Zelira Therapeutics Aktienanalyse

What does Zelira Therapeutics do?

Zelira Therapeutics was founded in 2016 with its headquarters in Perth, Australia. The company focuses on the development, production, and marketing of medical cannabis to meet the needs of patients worldwide. The company's business model is based on producing medical cannabis specifically tailored to patients' needs. It works closely with doctors and patients to ensure its products are effective and meet patients' needs. Zelira Therapeutics operates in three main areas. The first is the development of products for treating pain and inflammation in chronic conditions such as multiple sclerosis, cancer, and epilepsy. The second area includes the development of products for treating sleep disorders. The third area is the development of products for treating mental disorders such as anxiety and depression. The company has developed a wide range of products, including oils, pills, sprays, and topical creams. An example of a product is the ZTL-101 oil, which was developed for treating pain and inflammation in patients with osteoarthritis. The oil contains a combination of CBD and THC. The company has also partnered with the University of Mississippi to research the use of medical cannabis for treating post-traumatic stress disorder (PTSD). The research is funded by the US government and aims to legitimize the use of medical cannabis for treating PTSD. Zelira Therapeutics has also formed partnerships with other companies and organizations to advance its research and development. In 2020, the company entered into an agreement with Emerald Health Therapeutics, a Canadian company specializing in the production of medical cannabis. The two companies will collaborate on developing products for treating sleep disorders. The company has also partnered with iCAN Israel-Cannabis, an Israel-based company specializing in the research and development of medical cannabis. The two companies are working together to develop new products and promote the use of medical cannabis in various countries. In addition to its partnerships, Zelira Therapeutics has established a strong presence in various international markets. It is currently operating in the US, Australia, New Zealand, and Germany, and is working to expand into other countries. Overall, Zelira Therapeutics is a company specializing in the development of medical cannabis for treating various conditions. It has a wide range of products and works closely with doctors and patients to ensure their effectiveness and meet patients' needs. With strong partnerships and a presence in various international markets, the company has a promising future. Zelira Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Zelira Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Zelira Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Zelira Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Zelira Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Zelira Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Zelira Therapeutics stock

What is the price-to-earnings ratio of Zelira Therapeutics?

The price-earnings ratio of Zelira Therapeutics is currently -0.12.

How has the price-earnings ratio of Zelira Therapeutics changed compared to last year?

The price-to-earnings ratio of Zelira Therapeutics has increased by -36.84% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Zelira Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Zelira Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Zelira Therapeutics affect the company?

An increase in the price-earnings ratio of Zelira Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Zelira Therapeutics affect the company?

A decrease in the price-earnings ratio of Zelira Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Zelira Therapeutics?

Some factors that influence the price-earnings ratio of Zelira Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Zelira Therapeutics pay?

Over the past 12 months, Zelira Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zelira Therapeutics is expected to pay a dividend of 0 AUD.

What is the dividend yield of Zelira Therapeutics?

The current dividend yield of Zelira Therapeutics is .

When does Zelira Therapeutics pay dividends?

Zelira Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zelira Therapeutics?

Zelira Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Zelira Therapeutics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zelira Therapeutics located?

Zelira Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zelira Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zelira Therapeutics from 6/18/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 6/18/2025.

When did Zelira Therapeutics pay the last dividend?

The last dividend was paid out on 6/18/2025.

What was the dividend of Zelira Therapeutics in the year 2024?

In the year 2024, Zelira Therapeutics distributed 0 AUD as dividends.

In which currency does Zelira Therapeutics pay out the dividend?

The dividends of Zelira Therapeutics are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Zelira Therapeutics

Our stock analysis for Zelira Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zelira Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.